非对称性二甲基精氨酸与血管病变的关系

非对称性二甲基精氨酸（ADMA）是内源性一氧化氮合酶（NOS）抑制剂，可以抑制血管活性物质一氧化氮（NO）生成，导致内皮功能障碍，是一种新的内皮功能障碍预测因子。研究表明，ADMA是动脉粥样硬化、高血压、缺血性脑卒中的危险因素，ADMA可能通过引起脑血流自我调节障碍、慢性低灌注和血脑屏障受损参与脑白质疏松的发生和发展。干扰ADMA的合成或代谢可能为防治血管病变开辟一条新途径。

Relationship of asymmetric dimethylarginine with vasculopathy

Asymmetric dimethylarginine （ADMA） is an endogenous inhibitor of endothelial nitric oxide synthase （NOS）, which inhibits the formation of vasoactive substance, nitric oxide （NO）, and further results in endothelial dysfunction. It is considered as a new predictor for endothelial dysfunction. Some researches have shown that ADMA is a risk factor of atherosclerosis, hypertension and ischemic stroke. In recent years, studies also showed that ADMA may cause cerebral blood flow autoregulation dysfunction, chronic low perfusion and blood-brain barrier damage, and is involved in the incidence and development of leukoaraiosis. Interference of the synthesis or metabolism of ADMA may bring forward a new means for the prevention and treatment of vasculopathy.